Key facts
- Ridge Bio’s last known valuation is $65.0M (Sep 2025).
- It has raised $24.7M; the latest was Seed Round ($24.7M) in Sep 2025.
- Notable investors include Sutter Hill Ventures, Overlap Holdings.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Ridge Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Ridge Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ridge Bio
Developer of precision enzymes and targeted drug delivery systems designed to advance the development of precision medicines. The company offers an experiment-informed artificial intelligence platform that supports antibody-drug conjugates, chimeric antigen receptor T lymphocyte therapies, nucleic acid delivery, biocatalysts, radiotherapies, and enzyme-based therapeutics, enabling pharmaceutical researchers to improve specificity and therapeutic performance.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2024
- Website
- ridgebio.com/
- Ownership
- Privately Held (backing)
Ridge Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ridge Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ridge Bio in its N-PORT filings yet. We sweep new filings monthly.